The Tangential Dialogue Between Science and Medicine : A Case in Point
Published by Elsevier Inc..
The road between a hypothesis about a disease or condition and its cure or palliation is never simply linear. There are many tantalizing tangents to be chased and many seemingly obvious truths with countless exceptions; this is usually a feature, not a bug, as they say in computer programming. In the tangents and exceptions are clues and alternative roads to science and medicine that can provide cures and palliative measures, sometimes for diseases or conditions other than the one being studied. The narrative that follows uses the author's scientific experience in childhood nervous system cancer to illustrate the importance of a robust, bidirectional interaction between the laboratory bench and the clinic bedside in the quest for solutions to problems of health, longevity, and quality of life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
Pediatric neurology - 153(2024) vom: 27. März, Seite 96-102 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schor, Nina F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemotherapy |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pediatrneurol.2024.01.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368496163 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368496163 | ||
| 003 | DE-627 | ||
| 005 | 20240316232752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pediatrneurol.2024.01.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM368496163 | ||
| 035 | |a (NLM)38359527 | ||
| 035 | |a (PII)S0887-8994(24)00030-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schor, Nina F |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Tangential Dialogue Between Science and Medicine |b A Case in Point |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Elsevier Inc. | ||
| 520 | |a The road between a hypothesis about a disease or condition and its cure or palliation is never simply linear. There are many tantalizing tangents to be chased and many seemingly obvious truths with countless exceptions; this is usually a feature, not a bug, as they say in computer programming. In the tangents and exceptions are clues and alternative roads to science and medicine that can provide cures and palliative measures, sometimes for diseases or conditions other than the one being studied. The narrative that follows uses the author's scientific experience in childhood nervous system cancer to illustrate the importance of a robust, bidirectional interaction between the laboratory bench and the clinic bedside in the quest for solutions to problems of health, longevity, and quality of life | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Neuroblastoma | |
| 650 | 4 | |a Neurotrophins | |
| 650 | 4 | |a Protein methylation | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 4 | |a Transcription factors | |
| 650 | 4 | |a Translational research | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric neurology |d 1993 |g 153(2024) vom: 27. März, Seite 96-102 |w (DE-627)NLM012947210 |x 1873-5150 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2024 |g day:27 |g month:03 |g pages:96-102 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pediatrneurol.2024.01.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2024 |b 27 |c 03 |h 96-102 | ||